Lavaca Capital’s AbbVie ABBV Stock Holding History

Lavaca Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,600	Closed	-$1.32M	–	134
2022 Q2	$1.32M	Sell	8,600 -700	-8%	-$107K	0.2%	52
2022 Q1	$1.51M	Sell	9,300 -200	-2%	-$29.1K	0.16%	67
2021 Q4	$1.29M	Sell	9,500 -300	-3%	-$35.4K	0.17%	71
2021 Q3	$1.06M	Hold	9,800	–	–	0.11%	89
2021 Q2	$1.1M	Buy	+9,800	New	+$1.1M	0.11%	78

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lavaca Capital's ABBV Position: Q1 2026 in Review

Lavaca Capital increased its AbbVie (ABBV) stake by 22% in Q1 2026, buying an estimated $85.2K and bringing the position to 2,169 shares worth $472K. The position accounts for 0.08% of the portfolio, ranked #71.

Lavaca Capital first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $8.54M in Q2 2021. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Lavaca Capital held 2,169 shares of AbbVie worth $472K as of Q1 2026.
Lavaca Capital bought 384 AbbVie shares in Q1 2026, an estimated $85.2K.
AbbVie made up 0.08% of Lavaca Capital's portfolio in Q1 2026, its #71 holding.
Lavaca Capital first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
Lavaca Capital's AbbVie position peaked at $8.54M in Q2 2021.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Lavaca Capital's 13F filing for Q1 2026, filed 13 May 2026.